Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCLI Brainstorm Cell Therapeutics	$1.06 -2.8%	$1.15	$0.72 ▼ $6.45	$10.72M	0.24	385,379 shs	419,864 shs
GLYC GlycoMimetics	$0.16 -6.6%	$18.40	$14.06 ▼ $63.00	$10.00M	1.62	63,710 shs	1.05 million shs
IBIO iBio	$0.76 +6.3%	$0.85	$0.64 ▼ $6.89	$12.47M	0.96	837,693 shs	2.02 million shs
NKGN NKGen Biotech	$0.24 +7.2%	$0.25	$0.10 ▼ $1.37	$10.80M	1.2	1.57 million shs	71,585 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCLI Brainstorm Cell Therapeutics	-2.75%	-13.11%	0.00%	-10.92%	-81.94%
GLYC GlycoMimetics	0.00%	0.00%	-99.29%	-99.29%	-99.47%
IBIO iBio	+6.34%	-2.08%	-6.33%	-81.67%	-63.53%
NKGN NKGen Biotech	+7.23%	-3.92%	-12.65%	+47.09%	-81.52%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCLI Brainstorm Cell Therapeutics	4.445 of 5 stars	3.5	4.0	4.7	3.3	0.8	0.6
GLYC GlycoMimetics	1.6853 of 5 stars	0.0	3.0	4.6	3.0	1.7	0.0
IBIO iBio	1.5914 of 5 stars	3.5	0.0	0.0	1.8	0.0	0.6
NKGN NKGen Biotech	0.3632 of 5 stars	0.0	3.0	0.0	0.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCLI Brainstorm Cell Therapeutics	3.00	Buy	$30.00	2,730.19% Upside
GLYC GlycoMimetics	2.50	Moderate Buy	N/A	N/A
IBIO iBio	3.00	Buy	$4.30	469.54% Upside
NKGN NKGen Biotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest IBIO, GLYC, NKGN, and BCLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
5/5/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	($1.36) per share	N/A
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94
IBIO iBio	$375K	33.26	N/A	N/A	$1.41 per share	0.54
NKGN NKGen Biotech	$80K	134.96	N/A	N/A	($2.68) per share	-0.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCLI Brainstorm Cell Therapeutics	-$11.62M	-$3.36	N/A	N/A	N/A	N/A	N/A	-519.50%	8/13/2025 (Estimated)
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	8/6/2025 (Estimated)
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
NKGN NKGen Biotech	-$82.94M	-$2.45	N/A	∞	N/A	N/A	N/A	-479.36%	N/A

Latest IBIO, GLYC, NKGN, and BCLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	BCLI Brainstorm Cell Therapeutics	-$0.38	-$0.45	-$0.07	-$0.45	N/A	N/A
5/14/2025	Q1 2025	GLYC GlycoMimetics	-$5.00	-$4.00	+$1.00	-$0.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCLI Brainstorm Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A
NKGN NKGen Biotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCLI Brainstorm Cell Therapeutics	N/A	0.21	0.21
GLYC GlycoMimetics	N/A	1.92	1.92
IBIO iBio	0.05	1.76	1.76
NKGN NKGen Biotech	N/A	0.02	0.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCLI Brainstorm Cell Therapeutics	14.33%
GLYC GlycoMimetics	75.19%
IBIO iBio	7.90%
NKGN NKGen Biotech	76.17%

Insider Ownership

Company	Insider Ownership
BCLI Brainstorm Cell Therapeutics	11.15%
GLYC GlycoMimetics	8.70%
IBIO iBio	0.58%
NKGN NKGen Biotech	10.36%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCLI Brainstorm Cell Therapeutics	40	9.84 million	7.05 million	Optionable
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable
IBIO iBio	100	16.52 million	9.82 million	N/A
NKGN NKGen Biotech	N/A	44.95 million	40.29 million	Not Optionable

IBIO, GLYC, NKGN, and BCLI Headlines

Recent News About These Companies

NKGen Biotech Announces International and U.S. Expansion of Phase 1/2a Troculeucel Alzheimer's Trial with Activation of Clinical Sites in Canada and Florida

June 23, 2025 | globenewswire.com

Nkgen biotech sees $2.5 million stock purchase by major shareholder

June 4, 2025 | investing.com

NKGen Biotech Enters Stock Purchase Agreement

May 20, 2025 | tipranks.com

NKGen CEO puts skin in the game, investing $2.6M to move biotech toward Alzheimer’s readout

May 8, 2025 | fiercebiotech.comF

NKGen Biotech Chairman & CEO Paul Y. Song, M.D.

May 8, 2025 | globenewswire.com

NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting

May 7, 2025 | finance.yahoo.com

NKGen Biotech To Present on the Use of Troculeucel for Alzheimer's and Parkinson's Disease at the 7th China International Biotechnology Conference & Exhibition

April 14, 2025 | globenewswire.com

NKGen Biotech presents data from Phase 1/2a trial of troculeucel

April 9, 2025 | markets.businessinsider.com

NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer's Disease at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

April 7, 2025 | globenewswire.com

NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference

March 27, 2025 | nasdaq.com

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025)

March 25, 2025 | markets.businessinsider.com

NKGen Biotech To Present Updated Troculeucel Data at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™ 2025)

March 25, 2025 | globenewswire.com

NKGen Biotech Treats First Stroke Patient With Troculeucel Cell Therapy

March 5, 2025 | precisionmedicineonline.comP

NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split

March 4, 2025 | markets.businessinsider.com

NKGen Biotech, Inc. Transitions to OTC Markets Following Nasdaq Delisting, Retaining Compliance with SEC Reporting Requirements

March 4, 2025 | quiverquant.comQ

NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented

March 4, 2025 | globenewswire.com

NKGen Biotech announces administration of first dose of troculeucel

March 3, 2025 | markets.businessinsider.com

NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program

March 3, 2025 | globenewswire.com

NKGen administers first troculeucel dose under compassionate use program

February 21, 2025 | markets.businessinsider.com

NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program

February 21, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, GLYC, NKGN, and BCLI Company Descriptions

Brainstorm Cell Therapeutics NASDAQ:BCLI

$1.06 -0.03 (-2.75%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.08 +0.02 (+1.89%)

As of 06/27/2025 07:58 PM Eastern

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-6.63%)

Closing price 06/13/2025

Extended Trading

$0.16 0.00 (0.00%)

As of 06/13/2025 07:49 PM Eastern

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

iBio NYSE:IBIO

$0.76 +0.05 (+6.34%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.73 -0.03 (-3.84%)

As of 06/27/2025 07:56 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

NKGen Biotech NYSE:NKGN

$0.24 +0.02 (+7.23%)

As of 06/27/2025 03:13 PM Eastern

NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time